| Literature DB >> 28533915 |
Marte Strømsnes Larssen1,2, Kjetil Steine1,3, Janne Mykland Hilde3, Ingunn Skjørten4, Christian Hodnesdal1,2, Knut Liestøl5, Knut Gjesdal1,2.
Abstract
OBJECTIVE: Patients with chronic obstructive pulmonary disease (COPD) often have abnormal ECGs. Our aim was to separate the effects on ECG by airway obstruction, emphysema and right ventricular (RV) afterload in patients with COPD.Entities:
Keywords: chronic lung disease; electrocardiography; pulmonary vascular disease
Year: 2017 PMID: 28533915 PMCID: PMC5437720 DOI: 10.1136/openhrt-2016-000552
Source DB: PubMed Journal: Open Heart ISSN: 2053-3624
Electrocardiographic signs commonly related to COPD
| Emphysema | P-wave axis |
| Right-atrium enlargement | P-amplitude in II, III or aVF ≥2.5 mm |
| P-amplitude in V1 ≥1.5 mm | |
| Scott | R in V1 ≥7 mm |
| R/S in V1 >1 | |
| VAT in V1 >35 ms | |
| Sokolow-Lyon: RVH | R in V1 + S in V5 or V6 >10.5 mm |
| Clockwise rotation | R/S ratio in V5 ≤1 |
| Low voltage limb leads | QRS (R+S) <5 mm in I, II, aVF, III (all)* |
| Low voltage precordial leads | QRS <10 mV in V1–V6 (all)* |
| S1S2S3 pattern | Dominant S in I, II, III (all) |
| QS complex | Lead III |
| Right-axis deviation: | >90° |
| Left-axis deviation: | <-30° to −90° |
| Elevated resting heart rate | HR >80 beats/min* |
*Minnesota Code20
HR, heart rate; RVH, right ventricular hypertrophy; VAT, ventricular activation time.
ECG measurements and prevalence of various ECG findings
| ECG variables | Controls | GOLD | Controls vs COPD | GOLD stage | ||
| n=32 | 2 (n=40) | 3 (n=30) | 4 (n=31) | p | p | |
| -axis (°) | 52 (21) | 67 (26) | 64 (41) | 69 (22) | 0.72 | |
| P in V1 (mm) | 0.6 (0.2) | 0.6 (0.4) | 0.5 (0.5) | 0.2 (0.7) | ||
| P in II, aVF, III (mm) | 1.3 (0.5) | 1.3 (0.6) | 1.3 (0.8) | 1.3 (0.8) | 0.92 | 0.94 |
| QRS duration (ms) | 91 (13) | 87 (16) | 88 (15) | 83 (12) | 0.09 | 0.46 |
| QRS-axis (°) | 34 (42) | 60 (27) | 75 (37) | 45 (55) | 0.94 | |
| V1 R/S | 0.2 (0.2) | 0.4 (0.6) | 0.5 (0.9) | 0.2 (0.2) | 0.98 | 0.38 |
| V2 R/S | 0.6 (0.4) | 0.8 (1.3) | 0.6 (0.9) | 0.4 (0.5) | ||
| V3 R/S | 2.0 (3.1) | 1.8 (2.3) | 1.3 (1.2) | 1.0 (1.6) | ||
| V4 R/S | 5.7 (6.4) | 4.4 (7.5) | 4.2 (6.2) | 2.8 (3.8) | 0.10 | |
| V5 R/S | 10.2 (11.4) | 6.5 (7.4) | 6.2 (7.4) | 4.1 (5.0) | ||
| SL RVH (mm) | 4 (3) | 5 (3) | 6 (5) | 5 (4) | 0.07 | 0.50 |
| SL RVH p. (mm·ms) | 354 (251) | 415 (286) | 524 (479) | 451 (325) | 0.17 | 0.66 |
| SL LVH (mm) | 20 (6) | 20 (6) | 18 (6) | 14 (6) | 0.07 | |
| Cornell Index (mm) | 13 (6) | 12 (5) | 12 (5) | 15 (6) | 0.98 | 0.12 |
| Cornell p. (mm·ms) | 1243 (734) | 1053 (470) | 1070 (504) | 1234 (539) | 0.61 | 0.17 |
| R+S precordial leads | 81 (20) | 80 (18) | 77 (22) | 67 (19) | 0.13 | |
| R+S frontal leads | 24 (8) | 24 (5) | 23 (7) | 20 (6) | 0.32 | |
| Precordial/frontal amp | 3.5 (0.8) | 3.5 (0.9) | 3.6 (1.6) | 3.8 (1.8) | 0.47 | 0.96 |
| CCW n (%) | 18 (60) | 17 (43) | 12 (40) | 5 (16) | ||
| Clockwise n (%) | 3 (9) | 5 (13) | 7 (23) | 10 (32) | 0.15 | 0.11 |
| Prevalence of various ECG findings | ||||||
| Abnormal ECG | 8 (25%) | 34 (85%) | 20 (67%) | 29 (94%) | 0.49 | |
| HR >80 beats/min | 4 (13%) | 24 (60%) | 15 (50%) | 22 (71%) | 0.44 | |
| P-axis:<0°or>75° | 1 (3%) | 10 (25%) | 10 (34%) | 9 (29%) | 0.65 | |
| P-pulmonale | 0 (0%) | 4 (10%) | 2 (7%) | 2 (6%) | 0.18 | 0.57 |
| QRS <70 or>120 ms | 1 (3%) | 12 (30%) | 7 (23%) | 5 (16%) | 0.18 | |
| QRS-axis −30° to 90° | 29 (84%) | 40 (100%) | 28 (93%) | 24 (77%) | 1.0000 | |
| Left axis −31° to −90° | 3 (16%) | 0 (0%) | 0 (0%) | 5 (16%) | 0.40 | |
| Right axis >90° | 0 (0%) | 0 (0%) | 2 (7%) | 2 (6%) | 1.0000 | 0.14 |
| Low voltage I–III | 1 (3%) | 0 (0%) | 1 (3%) | 1 (3%) | 0.57 | 0.31 |
| R/S in V1>1 | 0 (0%) | 1 (3%) | 2 (7%) | 3 (10%) | 0.34 | 0.20 |
| R/S in V5<1 | 0 (0%) | 3 (8%) | 3 (10%) | 1 (3%) | 0.19 | 0.57 |
| S1S2S3 pattern | 2 (7%) | 1 (3%) | 2 (8%) | 7 (23%) | 0.73 | |
| RVH SL | 0 (0%) | 0 (0%) | 1 (3%) | 3 (10%) | 0.57 | |
| RVH Scott | 1 (3%) | 2 (5%) | 3 (10%) | 2 (6%) | 0.68 | 0.75 |
| RVH Scott or SL | 0 (3%) | 3 (8%) | 4 (13 %) | 1 (4%) | 0.20 | 0.73 |
Values are mean (SD) of continuous variables.
Bold values are statistically significant. p Values refer to Kendall’s t- correlation for trend comparing GOLD stage II, III and IV for each variable and Wilcoxon/ Kruskal-Wallis Rank Sum Test comparing COPD and controls, with Chi square approximation.
amp, amplitudes; Cornell p, Cornell product; CCW, counter-clockwise; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, heart rate; p, p value; SL RVH, Sokolow-Lyon right ventricular hypertrophy; SL RVH p, Sokolow-Lyon product; SL LVH, Sokolow-Lyon left ventricular hypertrophy.
Clinical characteristics of the study population
| Controls | GOLD | Controls vs COPD | GOLD stage | |||
| (n=32) | 2 (n=40) | 3 (n=30) | 4 (n=31) | p | p | |
| Women/men | 18/14 | 20/20 | 15/15 | 18/13 | 0.84 | 0.53 |
| Age (years) | 63 (7) | 65 (6) | 63 (8) | 63 (6) | 0.61 | 0.16 |
| BMI (kg/m2) | 25 (3) | 25 (4) | 25 (5) | 22 (6) | 0.76 | |
| Current smokers, n (%) | 2 (6) | 17 (43) | 5 (17) | 10 (32) | 0.26 | |
| HR (beats/min) | 66 (12) | 81 (17) | 81 (16) | 88 (18) | 0.22 | |
| SBP (mm Hg) | 121 (17) | 144 (21) | 136 (21) | 137 (23) | 0.20 | |
| DBP (mm Hg) | 76 (13) | 70 (12) | 69 (10) | 67 (14) | 0.20 | |
| mPAP (mm Hg) | – | 18 (4) | 20 (6) | 25 (6) | – | |
| PAC (mL/mm Hg) | – | 4.0 (1.1) | 4.2 (1.6) | 3.2 (1.4) | – | |
| PVR (Wu) | – | 1.8 (0.7) | 2.0 (0.8) | 3.3 (1.4) | – | |
| CI (L/min/m2) | – | 2.9 (0.4) | 2.9 (0.5) | 3.1 (0.6) | – | 0.35 |
| RV EDV (mL) | 107 (22) | 126 (34) | 137 (39) | 121 (27) | 0.67 | |
| LV EDV (mL) | 109 (24) | 113 (26) | 115 (31) | 94 (28) | 0.77 | |
| RV/LV EDVI | 1.0 (0.1) | 1.1 (0.2) | 1.2 (0.2) | 1.3 (0.3) | ||
| RV wall thickness (mm) | 3.5 (0,5) | 5.2 (0.8) | 5.8 (1) | 6.5 (1.2) | ||
| FEV1 (L) | 3.1 (0.8) | 1.8 (0.6) | 1.2 (0.4) | 0.7 (0.2) | ||
| FEV1/FVC (%) | 76 (4) | 56 (7) | 45 (10) | 40 (10) | ||
| FEV1% predicted | – | 59 (8) | 39 (6) | 26 (7) | – | |
| DLCO % predicted | – | 64 (14) | 53 (17) | 29 (14) | – | |
| Residual volume (L) | 2.6 (0.4) | 4.6 (0.7) | 4.5 (1.2) | 5.6 (1.2) | ||
| Residual volume % pred. | 118 (16) | 161 (32) | 205 (64) | 262 (47) | ||
| TLC (L) | 6.9 (1.3) | 6.9 (1.2) | 7.3 (1.4) | 7.8 (1.6) | 0.39 | |
| TLC % predicted | 112 (11) | 117 (15) | 125 (28) | 137 (20) | ||
| Residual volume/TLC (%) | 39 (5) | 52 (8) | 61 (11) | 72 (5) | ||
| SaO2 (%) | – | 96 (1) | 96 (1) | 91 (5) | – | |
| PaO2 (kPa) | – | 10.1 (1.0) | 9.7 (1.2) | 7.9 (1.3) | – | |
| PaCO2 (kPa) | – | 5.1 (0.4) | 5.4 (0.6) | 6.0 (0.8) | – | |
Bold values are statistically significant.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; DLCO, diffusion capacity for carbon monoxide of the lungs; FEV1/FVC, forced expiratory volume in 1 s/forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, heart rate; LV EDV, left ventricular end-diastolic volume; mPAP, mean pulmonary artery pressure; PAC, pulmonary arterial compliance; PaO2, arterial oxygen tension; PaCO2, arterial carbon dioxide tension; PVR, pulmonary vascular resistance; RV EDV, right ventricular end-diastolic volume; RV/LV EDVI, right ventricle/ left ventricle end-diastolic volume ratio; SBP, systolic blood pressure; SaO2, arterial oxygen saturation; TLC, total lung capacity.
Independent predictors of ECG findings in patients with COPD
| ECG | Predictors | β-coefficient (SE) | 95% CI | p Value | R2 adj |
| Heart rate | 0.04 | ||||
| BMI | 0.3771 (0.3890) | (−0.3954 to 1.1496) | 0.34 | ||
| Obstruction | −2.4663 (2.5794) | (−7.5879 to 2.6552) | 0.34 | ||
| Emphysema | 3.3934 (1.4087) | (0.5963 to 6.1905) | |||
| Log (P-wave V1) | 0.08 | ||||
| BMI | −0.0083 (0.0120) | (−0.0323 to 0.0156) | 0.49 | ||
| Obstruction | −0.1431 (0.0721) | (−0.2870 to 0.0007) | |||
| Emphysema | 0.0638 (0.0420) | (−0.01994 to 0.1476) | 0.13 | ||
| Afterload | −0.0311 (0.0214) | (−0.0738 to 0.0115) | 0.15 | ||
| RV/LV EDVI | 0.6196 (0.2190) | (0.1832 to 1.0561) | |||
| Log (QRS duration) | 0.06 | ||||
| Gender* | −0.0311 (0.0166) | (−0.0641 to 0.0017) | 0.06 | ||
| Afterload | 0.0084 (0.0060) | (−0.0036 to 0.0204) | 0.17 | ||
| RV/LV EDVI | −0.1458 (0.0744) | (−0.2936 to 0.0020) | |||
| Log (180-QRS axis)† | |||||
| Gender* | 0.0309 (0.0282) | (−0.0251 to 0.0868) | 0.28 | ||
| BMI | 0.0170 (0.0059) | (0.0020 to 0.0288) | |||
| Obstruction | 0.0382 (0.0288) | (−0.0190 to 0.0954) | 0.19 | ||
| RV/LV EDVI | −0.1579 (0.1187) | (−0.3935 to 0.0777) | 0.19 | ||
| R+S precordial leads | 0.07 | ||||
| Obstruction | 5.8220 (3.1490) | (−0.4371 to 12.0811) | 0.08 | ||
| Emphysema | −3.7882 (1.6900) | (−7.1473 to –0.4291) | |||
| Afterload | −0.1184 (0.9034) | (−1.9140 to 1.6772) | 0.90 | ||
| RV/LV EDVI | −15.9687 (9.1503) | (−34.1560 to 2.2187) | 0.09 | ||
| R+S frontal leads | 0.11 | ||||
| Gender* | 0.8272 (0.6782) | (−0.5214 to 2.1757) | 0.23 | ||
| BMI | −0.3702 (0.1447) | (−0.6580 to –0.0823) | |||
| Obstruction | 1.4496 (1.0280) | (−0.5944 to 3.4936) | 0.16 | ||
| Emphysema | −1.5747 (0.6008) | (−2.7693 to –0.3800) | |||
| Afterload | −0.1662 (0.2817) | (−0.7263 to 0.3939) | 0.56 | ||
| RV/LV EDVI | −3.2500 (2.8746) | (−8.9655 to 2.4656) | 0.26 | ||
| Log (Sokolow-Lyon RVH) | 0.19 | ||||
| Gender* | −0.0453 (0.0708) | (−0.1861 to 0.0956) | 0.52 | ||
| BMI | 0.0383 (0.0151) | (0.0082 to 0.0684) | |||
| Obstruction | 0.2523 (0.1074) | (0.0388 to 0.4657) | |||
| Emphysema | −0.1090 (0.0627) | (−0.2338 to 0.0157) | 0.09 | ||
| Afterload | 0.0825 (0.0294) | (0.0241 to 0.1411) | |||
| RV/LV EDVI | −0.6141 (0.3002) | (−1.2110 to –0.0172) | |||
| Log (Sokolow-Lyon RVH product) | 0.20 | ||||
| Gender* | −0.0720 (0.0761) | (−0.2235 to 0.0795) | 0.35 | ||
| BMI | 0.0389 (0.0162) | (0.0065 to 0.0712) | |||
| Obstruction | 0.2560 (0.1155) | (0.0264 to 0.4856) | |||
| Emphysema | −0.1180 (0.0675) | (−0.2521 to 0.0162) | 0.08 | ||
| Afterload | 0.0947 (0.0317) | (0.0317to 0.1575) | |||
| RV/LV EDVI | −0.7719 (0.3229) | (−1.4140 to –0.1298) | |||
| Sokolow Lyon left ventricular hypertrophy | 0.08 | ||||
| Gender* | −0.5269 (0.6870) | (−1.8927 to 0.8388) | 0.45 | ||
| BMI | −0.1964 (0.1482) | (−0.4912 to 0.0983) | 0.19 | ||
| Obstruction | −0.3134 (1.0412) | (−2.3834 to 1.7565) | 0.76 | ||
| Emphysema | −0.3042 (0.6073) | (−1.5156 to 0.9030) | 0.62 | ||
| Afterload | −0.5327 (0.2660) | (−1.0615 to –0.0038) | |||
| Cornell Index model 1 | 0.34 | ||||
| Gender* | 3.2567 (0.4886) | (2.2860 to 4.2275) | |||
| BMI | 0.1759 (0.1030) | (−0.0288 to 0.3807) | 0.09 | ||
| Afterload | 0.3542 (0.1778) | (0.0009 to 0.7076) | |||
| RV/LV EDVI | −0.2416 (2.1360) | (−4.4851 to 4.0019) | 0.91 | ||
| Cornell Index model 2 | 0.34 | ||||
| Gender* | 3.3363 (0.4697) | (2.4037 to 4.2687) | |||
| BMI | 0.1697 (0.0992) | (−0.0272 to 0.0366) | 0.09 | ||
| Obstruction | 0.9709 (0.4815) | (0.0150 to 1.9267) | |||
| RV/LV EDVI | 0.2188 (1.9797) | (−3.7109 to 4.1486) | 0.91 | ||
Multiple linear regression analysis.
Bold values are statistically significant. p Value refers to t-test of regression coefficient.
*Female as reference category.†Log (180-QRS axis): increased value reflects a more leftward axis.
R2 adj, adjusted R2; BMI, body mass index; COPD, chronic obstructive pulmonary disease; RV/LV EDVI, right ventricle/left ventricle end-diastolic volume ratio; RVH, right ventricular hypertrophy.
Independent predictors for horizontal clockwise rotation of the QRS-axis
| ECG | Independent variable | β | OR | 95% CI | p Value | R2 adj |
| Model 1 | 0.18 | |||||
| Gender* | −0.0147 | 1.0298 | (0.3138 to 3.3553) | 0.96 | ||
| BMI | 0.1465 | 1.1578 | (1.0277 to 1.3238) | |||
| Obstruction | 0.6057 | 1.8325 | (0.7400 to 4.8112) | 0.20 | ||
| Emphysema | −0.1698 | 0.8437 | (0.5020 to 1.3936) | 0.51 | ||
| Afterload | 0.1595 | 1.1730 | (0.9371 to 1.4739) | 0.16 | ||
| Model 2 | 0.16 | |||||
| Gender* | −0.0739 | 1.1594 | (0.4064 to 3.2821) | 0.78 | ||
| BMI | 0.1331 | 1.1424 | (1.0251 to 1.2867) | |||
| Obstruction | 0.5674 | 1.7638 | (1.0425 to 3.1681) | |||
| Model 3 | 0.16 | |||||
| Gender* | −0.0854 | 1.1864 | (0.3928 to 3.5702) | 0.76 | ||
| BMI | 0.1585 | 1.1717 | (1.0450 to 1.3344) | |||
| Afterload | 0.1894 | 1.2085 | (1.0103 to 1.4622) | |||
Multiple logistic regression analysis.
Bold values are statistically significant. p Values refer to Likelihood ratio Chi square test of the regression estimates.
*Female as reference category.
β, regression coefficient; R2 adj, adjusted R-square; BMI, body mass index; RV/LV EDVI, right ventricle end-diastolic volume ratio; RVH, right ventricular hypertrophy.
Single and composite predictor variables and their correlations
| GOLD | Correlation | ||||
| New variables | 2 (n=40) | 3 (n=30) | 4 (n=31) | t | p* |
| Obstruction (-FEV1%) | −1.0 (0.5) | 0.2 (0.4) | 1.1 (0.4) | 0.79 | |
| Emphysema (residual volume %, RV/TLC) | −1.4 (1.1) | −0.1 (1.9) | 1.9 (1.1) | 0.56 | |
| Afterload (mPAP, PVR,- PAC, RV wall) | −1.5 (1.7) | −0.7 (2.6) | 2.7 (2.9) | 0.45 | |
*p<0.05, p values refer to Kendall’s t correlation for trend between variables.
FEV1%, forced expiratory volume in 1 s % predicted; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mPAP, mean pulmonary artery pressure; PAC, pulmonary arterial compliance; PVR, pulmonary vascular resistance; RV/TLC, residual volume/total lung capacity; RV wall, right ventricle wall thickness; t, Kendalls t correlation.
Correlations between independent predictor variables
| Gender | BMI | Obstruction | Emphysema | Afterload | |
| BMI | |||||
| Obstruction | −0.0480 | ||||
| Emphysema | |||||
| Afterload | −0.1160 | ||||
| RV/LV EDVI | −0.1339 | −0.0703 |
Gender: female is a reference category for gender.
Bold values are statistically significant. Significant differences within each variable are indicated as:
*p<0.05; p values refers to Kendall’s t correlation.
BMI, body mass index; RV/LV EDVI, right ventricle/left ventricle end-diastolic volume ratio.